Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958417 | 0.91 | CYP2E1 (0.38) | CYP2E1NR1I2MCL1MEN1KMT2A | |
| SCHEMBL14982020 | 0.86 | CYP2E1 (0.38) | CYP2E1NR1I2MCL1 | |
| SCHEMBL14982034 | 0.83 | CYP2E1 (0.42) | CYP2E1NR1I2BCL2L1MCL1NPC1 | |
| SCHEMBL14982017 | 0.82 | CYP2E1 (0.47) | CYP2E1NR1I2NPC1RAB9AMEN1 | |
| SCHEMBL1958389 | 0.82 | CYP3A4 (0.34) | CYP2E1MEN1KMT2A | |
| SCHEMBL1960212 | 0.81 | NR1I2 (0.43) | CYP2E1NR1I2BCL2L1MCL1NPC1 | |
| SCHEMBL1960213 | 0.81 | NR1I2 (0.43) | CYP2E1NR1I2BCL2L1MCL1NPC1 | |
| SCHEMBL1958399 | 0.81 | FLT1 (0.35) | NPC1PKMRAB9AMEN1KMT2A | |
| SCHEMBL1961790 | 0.80 | CYP2E1 (0.36) | CYP2E1NR1I2RAB9AMEN1KMT2A | |
| SCHEMBL14985395 | 0.79 | CYP2E1 (0.37) | CYP2E1NR1I2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130136719-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136719-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, GTF3C3, ZC3HAV1 | CYP2E1 75/4885NR1I2 312/4885BCL2L1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.